Barclays’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $53.7K | Sell |
11,577
-100,271
| -90% | -$260K | ﹤0.01% | 4300 |
|
|
2026
Q1 | $312K | Buy |
111,848
+5,447
| +5% | +$16.6K | ﹤0.01% | 3455 |
|
|
2025
Q4 | $443K | Buy |
+106,401
| New | +$560K | ﹤0.01% | 3915 |
|
|
2025
Q2 | – | Sell |
-9,326
| Closed | -$11.4K | – | 5369 |
|
|
2025
Q1 | $11.4K | Sell |
9,326
-45,308
| -83% | -$63.6K | ﹤0.01% | 4858 |
|
|
2024
Q4 | $70.5K | Buy |
54,634
+26,047
| +91% | +$62.4K | ﹤0.01% | 4670 |
|
|
2024
Q3 | $78.6K | Buy |
28,587
+21,598
| +309% | +$53K | ﹤0.01% | 4633 |
|
|
2024
Q2 | $15.8K | Buy |
+6,989
| New | +$21.2K | ﹤0.01% | 4473 |
|
|
2021
Q4 | – | Sell |
-2,407
| Closed | -$9K | – | 4350 |
|
|
2021
Q3 | $9K | Sell |
2,407
-4,200
| -64% | -$14.2K | ﹤0.01% | 4531 |
|
|
2021
Q2 | $21K | Sell |
6,607
-24,487
| -79% | -$87.1K | ﹤0.01% | 4477 |
|
|
2021
Q1 | $68K | Buy |
31,094
+19,088
| +159% | +$42.8K | ﹤0.01% | 4129 |
|
|
2020
Q4 | $27K | Sell |
12,006
-5,274
| -31% | -$13.8K | ﹤0.01% | 4617 |
|
|
2020
Q3 | $46K | Sell |
17,280
-3,771
| -18% | -$10.6K | ﹤0.01% | 4650 |
|
|
2020
Q2 | $64K | Buy |
21,051
+7,669
| +57% | +$19.3K | ﹤0.01% | 4797 |
|
|
2020
Q1 | $27K | Sell |
13,382
-26,678
| -67% | -$64.9K | ﹤0.01% | 5537 |
|
|
2019
Q4 | $115K | Buy |
40,060
+20,188
| +102% | +$70.1K | ﹤0.01% | 5399 |
|
|
2019
Q3 | $72K | Sell |
19,872
-916
| -4% | -$3.31K | ﹤0.01% | 5714 |
|
|
2019
Q2 | $86K | Sell |
20,788
-111,603
| -84% | -$483K | ﹤0.01% | 5797 |
|
|
2019
Q1 | $677K | Sell |
132,391
-42,212
| -24% | -$203K | ﹤0.01% | 3829 |
|
|
2018
Q4 | $599K | Buy |
174,603
+168,393
| +2,712% | +$804K | ﹤0.01% | 3642 |
|
|
2018
Q3 | $37K | Buy |
6,210
+3,016
| +94% | +$16.6K | ﹤0.01% | 6230 |
|
|
2018
Q2 | $20K | Sell |
3,194
-16,929
| -84% | -$82.5K | ﹤0.01% | 6186 |
|
|
2018
Q1 | $96K | Buy |
+20,123
| New | +$93.8K | ﹤0.01% | 5415 |
|
|
2015
Q2 | – | Sell |
-574
| Closed | -$1K | – | 7070 |
|
|
2015
Q1 | $1K | Sell |
574
-837
| -59% | -$2.99K | ﹤0.01% | 6966 |
|
|
2014
Q4 | $4K | Buy |
1,411
+1,224
| +655% | +$5.41K | ﹤0.01% | 7014 |
|
|
2014
Q3 | $1K | Sell |
187
-208
| -53% | -$1.62K | ﹤0.01% | 7501 |
|
|
2014
Q2 | $5K | Buy |
395
+326
| +472% | +$4.06K | ﹤0.01% | 7112 |
|
|
2014
Q1 | $1K | Sell |
69
-3,231
| -98% | -$46K | ﹤0.01% | 7468 |
|
|
2013
Q4 | $26K | Buy |
3,300
+2,800
| +560% | +$25.9K | ﹤0.01% | 6563 |
|
|
2013
Q3 | $5K | Buy |
+500
| New | +$3.37K | ﹤0.01% | 6974 |
|
Other funds holding GALT
WANY
Barclays's GALT Position: Q2 2026 in Review
Barclays reduced its Galectin Therapeutics (GALT) stake by 90% in Q2 2026, selling an estimated $260K and leaving 11,577 shares worth $53.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4300.
Barclays first reported a position in GALT in Q3 2013 and has held it in 29 quarters since. The position peaked at $677K in Q1 2019. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Barclays held 11,577 shares of Galectin Therapeutics worth $53.7K as of Q2 2026.
- Barclays sold 100,271 Galectin Therapeutics shares in Q2 2026, an estimated $260K.
- Galectin Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4300 holding.
- Barclays first reported a position in Galectin Therapeutics in Q3 2013 and has held it in 29 quarters since.
- Barclays's Galectin Therapeutics position peaked at $677K in Q1 2019.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.